[1]黄柏生.阿司匹林联合替格瑞洛治疗急性冠状动脉综合征的抗血小板作用及副作用分析[J].医学信息,2025,38(11):154-157.[doi:10.3969/j.issn.1006-1959.2025.11.032]
　HUANG Baisheng.Analysis of Antiplatelet Effect and Side Effects of Aspirin Combined with Ticagrelor in the Treatment of Acute Coronary Syndrome[J].Journal of Medical Information,2025,38(11):154-157.[doi:10.3969/j.issn.1006-1959.2025.11.032]
点击复制

阿司匹林联合替格瑞洛治疗急性冠状动脉综合征的抗血小板作用及副作用分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年11期
页码:
154-157
栏目:
药物与临床
出版日期:
2025-06-01

文章信息/Info

Title:
Analysis of Antiplatelet Effect and Side Effects of Aspirin Combined with Ticagrelor in the Treatment of Acute Coronary Syndrome
文章编号:
1006-1959（2025）11-0154-04
作者:
黄柏生
峡江县中医院药剂科，江西 峡江 331400
Author(s):
HUANG Baisheng
Department of Pharmacy, Xiajiang County Hospital of Traditional Chinese Medicine, Xiajiang 331400， Jiangxi, China
关键词:
急性冠状动脉综合征; 阿司匹林; 替格瑞洛; 抗血小板治疗; 血小板参数; MACE; 副作用
Keywords:
Acute coronary syndrome;  Aspirin;  Ticagrelor;  Antiplatelet therapy;  Platelet parameters;  MACE;  Side effect
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2025.11.032
文献标志码:
A
摘要:
目的 探究阿司匹林联合替格瑞洛在急性冠状动脉综合征（ACS）治疗中的抗血小板作用及副作用。方法 选取2021年1月-2023年12月峡江县中医院收治的62例ACS患者，经随机数字表法分为对照组（31例）与观察组（31例），对照组采用阿司匹林抗血小板治疗，观察组采用阿司匹林+替格瑞洛抗血小板治疗，比较两组治疗前后的全球急性冠脉事件注册危险（GRACE）评分、胸痛TIMI评分、血小板参数[血小板计数（PLT）、平均血小板体积（MPV）、血小板最大聚集率（MAR）]、炎性因子水平[超敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）]、药物副作用、主要不良心血管事件（MACE）。结果 两组治疗后GRACE、TIMI评分低于治疗前，且观察组GRACE、TIMI评分低于对照组（P＜0.05）；两组治疗后PLT、MPV、MAR指标低于治疗前，且观察组PLT、MPV、MAR指标低于对照组（P＜0.05）；两组治疗后hs-CRP、IL-6水平均低于治疗前，且观察组hs-CRP、IL-6水平低于对照组（P＜0.05）；两组药物副作用比较，差异无统计学意义（P＞0.05）；治疗后3个月，观察组MACE发生率小于对照组（P＜0.05）。结论 阿司匹林联合替格瑞洛可减轻ACS患者的危险程度，减少血小板聚集，下调炎性指标，降低患者的MACE风险，副作用风险低。
Abstract:
Objective To explore the antiplatelet effect and side effects of aspirin combined with ticagrelor in the treatment of acute coronary syndrome (ACS). Methods A total of 62 patients with ACS admitted to Xiajiang County Hospital of Traditional Chinese Medicine from January 2021 to December 2023 were selected and divided into control group (31 patients) and observation group (31 patients) by random number table method. The control group was treated with aspirin antiplatelet therapy, and the observation group was treated with aspirin + ticagrelor antiplatelet therapy. The global acute coronary event registration risk (GRACE) score, chest pain TIMI score, platelet parameters [platelet count (PLT), mean platelet volume (MPV), platelet maximum aggregation rate (MAR)], inflammatory factor levels [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)], drug side effects, and major adverse cardiovascular events (MACE) were compared between the two groups before and after treatment. Results After treatment, the GRACE score and TIMI score of both groups decreased when compared with the baseline values, while the scores of the observation group were significantly lower than those of the control group (P<0.05). Meanwhile, the PLT, MPV, and MAR in both groups were reduced after treatment that compared with the baseline values, the values of PLT, MPV, and MAR in the observation group were significantly lower than those in the control group (P<0.05). In addition, the levels of hs-CRP and IL-6 decreased in both groups after treatment, and the levels of hs-CRP and IL-6 in the observation group were lower than those in the control group (P<0.05).There was no statistically significant difference in drug-related adverse effects between the two groups (P>0.05). During the 3-month follow-up period, the incidence of MACE was significantly lower in the observation group than that in the control group (P<0.05). Conclusion Aspirin combined with ticagrelor can reduce the risk of ACS patients, reduce platelet aggregation, down-regulate inflammatory indicators, reduce the risk of MACE in patients, and have low risk of side effects.

参考文献/References:

[1]栗佳男,王勇,邱洪,等.替格瑞洛和氯吡格雷在接受经皮冠状动脉介入治疗的非ST段抬高型急性冠状动脉综合征患者中有效性和安全性的比较研究[J].中国心血管杂志,2023,28(3):257-261.[2]赵庆忠,宋卫东,樊聪慧,等.替格瑞洛片联合阿司匹林对急性心肌梗死患者静脉血栓栓塞症发生率、凝血功能及不良反应发生率的影响[J].临床和实验医学杂志,2022,21(16):1704-1708.[3]陆治平,李益民,孟丹心,等.低剂量替格瑞洛对稳定性冠心病患者冠脉微循环及外周血MHR、NLR的影响[J].转化医学杂志,2022,11(3):151-154,141.[4]王子乾,邹宇婷,都日娜,等.真实世界急性冠状动脉综合征或经皮冠状动脉介入治疗术后患者替格瑞洛抗血小板降阶治疗的临床转归[J].中华老年多器官疾病杂志,2021,20(12):946-951.[5]李拜红,施晶晶,鲍骏,等.替格瑞洛片联合阿司匹林肠溶片用于经皮冠状动脉介入治疗术后急性心肌梗死患者的临床研究[J].中国临床药理学杂志,2021,37(19):2558-2561.[6]方昱,曹洁,许恩文,等.替格瑞洛联合阿司匹林治疗老年急性心肌梗死的心血管事件发生[J].中国老年学杂志,2021,41(13):2692-2695.[7]张新超,于学忠,陈凤英,等.急性冠脉综合征急诊快速诊治指南(2019)[J].临床急诊杂志,2019,20(4):253-262.[8]王悦,刘倍倍,陈蕾蕾,等.急性冠状动脉综合征患者经皮冠状动脉介入治疗术后接受小剂量替格瑞洛疗效的性别差异研究[J].中国介入心脏病学杂志,2021,29(6):337-341.[9]王军伟,卢亮,詹君华,等.低剂量替格瑞洛联合阿司匹林对高龄患者经皮冠状动脉介入治疗术后疗效的影响[J].北京医学,2021,43(6):578-581.[10]马铄,黄浩,韩虎魁,等.替格瑞洛应用于老年急性冠脉综合征直接经皮冠状动脉介入术后真实世界中的疗效研究[J].实用医院临床杂志,2021,18(3):13-16.[11]丁臻,吴炜,杨光耀.不同双联抗血小板方案对PCI手术患者心肌血流灌注的影响比较[J].川北医学院学报,2021,36(3):382-385.[12]田红娇,杜广清.阿司匹林联合替格瑞洛治疗IS/TIA导致的出血特征及危险因素分析[J].中风与神经疾病杂志,2021,38(1):28-31.[13]檀崇斌,朱倩,甘成伟,等.替格瑞洛联合阿托伐他汀与阿司匹林在急性冠状动脉综合症经皮冠状动脉介入术术后应用效果及安全性[J].临床军医杂志,2020,48(10):1243-1245.[14]伊兴旺,杨威.替格瑞洛维持服用与经皮冠状动脉介入治疗术后急性冠状动脉综合征患者心肺适能关系研究[J].临床军医杂志,2020,48(10):1212-1214.[15]王可,赵希坤,曲红培,等.阿司匹林联合替格瑞洛或氯吡格雷治疗冠心病不稳定型心绞痛的疗效观察[J].山西医药杂志,2020,49(19):2610-2612.[16]李刚,王立静,龙会平,等.替格瑞洛在急性冠状动脉综合征经皮冠状动脉介入治疗中的出血风险研究[J].河北医药,2020,42(12):1863-1866.[17]韩晓涛,董茜,陈永福,等.替格瑞洛联合阿托伐他汀对急性冠状动脉综合征患者高敏C反应蛋白及血脂水平的影响[J].中国医药,2020,15(7):1000-1003.[18]童随阳,蒋学俊,夏豪,等.替格瑞洛与氯吡格雷治疗急性ST段抬高型心肌梗死有效性和安全性的对比研究[J].实用心脑肺血管病杂志,2017,25(8):73-77.[19]欧阳莲,孟宪琴,刘伟,等.瑞舒伐他汀联合替格瑞洛对急性冠状动脉综合征患者血清炎症因子及内皮功能的影响分析[J].山西医药杂志,2020,49(10):1201-1204.[20]乔彩霞,王一然,王静,等.替格瑞洛联合阿司匹林治疗老年急性冠状动脉综合征的效果及对血清cTnT、BNP、CRP及D-D水平的影响[J].现代生物医学进展,2019,19(22):4353-4356,4375.[21]曾文峰,蔡楠,刘敬峰.替格瑞洛用于高龄患者经皮冠状动脉介入术后抗血小板治疗的疗效与安全性[J].中国医院用药评价与分析,2020,20(3):312-314,318.[22]陈宇,冯俊,周振宇,等.阿司匹林联合替格瑞洛对冠心病患者PCI术后炎症因子的改善作用[J].西部医学,2020,32(3):391-394.[23]高平峰,汪莲开.替格瑞洛对急性冠状动脉综合征患者经皮冠状动脉介入治疗后QT离散度及高敏C反应蛋白与可溶性CD40配体的影响[J].中国心血管病研究,2020,18(3):251-255.[24]刘豪,杨智勇.阿司匹林联合替格瑞洛或氯吡格雷对急性冠状动脉综合征患者高尿酸血症发生率影响的对比研究[J].中国心血管病研究,2020,18(3):256-259.[25]赵楠,齐斌.替格瑞洛联合阿司匹林在急性冠脉综合征治疗中的应用效果[J].中国药物滥用防治杂志,2021,27(5):692-695.

相似文献/References:

[1]张文魁.硝酸甘油联合阿司匹林治疗心绞痛的临床效果观察[J].医学信息,2018,31(02):119.[doi:10.3969/j.issn.1006-1959.2018.02.043]
　ZHANG Wen-kui.Clinical Effect of Nitroglycerin Combined with Aspirin in the Treatment of Angina Pectoris[J].Journal of Medical Information,2018,31(11):119.[doi:10.3969/j.issn.1006-1959.2018.02.043]
[2]宇英久,刘 杰.阿司匹林联合硫酸镁治疗妊娠高血压的疗效观察[J].医学信息,2018,31(06):133.[doi:10.3969/j.issn.1006-1959.2018.06.045]
　YU Ying-jiu,LIU Jie.Clinical Observation of Aspirin Combined with Magnesium Sulfate in the Treatment of Pregnancy-induced Hypertension[J].Journal of Medical Information,2018,31(11):133.[doi:10.3969/j.issn.1006-1959.2018.06.045]
[3]左洪亮.阿司匹林肠溶片治疗缺血性脑血管疾病的临床效果观察[J].医学信息,2018,31(18):118.[doi:10.3969/j.issn.1006-1959.2018.18.037]
　ZUO Hong-liang.Clinical Observation of Aspirin Enteric-coated Tablets in the Treatment of Ischemic Cerebrovascular Disease[J].Journal of Medical Information,2018,31(11):118.[doi:10.3969/j.issn.1006-1959.2018.18.037]
[4]肖智谦.急性冠脉综合征关联生化标记物的研究进展[J].医学信息,2018,31(20):23.[doi:10.3969/j.issn.1006-1959.2018.20.008]
　XIAO Zhi-qian.Advances in Research on Biochemical Markers Associated with Acute Coronary Syndrome[J].Journal of Medical Information,2018,31(11):23.[doi:10.3969/j.issn.1006-1959.2018.20.008]
[5]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Journal of Medical Information,2018,31(11):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]唐一飞,程宝山,王爱玲.不同时间服用小剂量阿司匹林对高血压患者血压影响的Meta分析[J].医学信息,2019,32(06):97.[doi:10.3969/j.issn.1006-1959.2019.06.030]
　TANG Yi-fei,CHENG Bao-shan,WANG Ai-ling.Meta-analysis of the Effects of Low-dose Aspirin on Blood Pressure in Patients with Hypertension at Different Times[J].Journal of Medical Information,2019,32(11):97.[doi:10.3969/j.issn.1006-1959.2019.06.030]
[7]梁道博,姚卜飞,夏双燕.氯吡格雷联合阿司匹林治疗急性冠脉综合征疗效与 安全性的Meta分析[J].医学信息,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
　LIANG Dao-bo,YAO Bu-fei,XIA Shuang-yan.Meta-analysis of the Efficacy and Safety of Clopidogrel Combined with Aspirin in the Treatment of Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
[8]黄 铃,孙 冰,蔡金美,等.维生素D治疗川崎病的疗效及其对血清促炎因子的影响[J].医学信息,2019,32(18):81.[doi:10.3969/j.issn.1006-1959.2019.18.025]
　HUANG Ling,SUN Bing,CAI Jin-mei,et al.Therapeutic Effect of Vitamin D on Kawasaki Disease and Its Effect on Serum Pro-inflammatory Factors[J].Journal of Medical Information,2019,32(11):81.[doi:10.3969/j.issn.1006-1959.2019.18.025]
[9]屈桓玮,吕松岑.全膝关节置换术后静脉血栓栓塞的预防研究[J].医学信息,2019,32(20):49.[doi:10.3969/j.issn.1006-1959.2019.20.014]
　QU Huan-wei,LYU Song-Cen.Prevention of Venous Thromboembolism after Total Knee Arthroplasty[J].Journal of Medical Information,2019,32(11):49.[doi:10.3969/j.issn.1006-1959.2019.20.014]
[10]廖丽萍,周跟东,张晓红.TyG指数对急诊PCI术后ACS患者预后的预测价值[J].医学信息,2021,34(04):123.[doi:10.3969/j.issn.1006-1959.2021.04.032]
　LIAO Li-ping,ZHOU Gen-dong,ZHANG Xiao-hong.The Predictive Value of TyG Index on the Prognosis of ACS Patients After Emergency PCI Surgery[J].Journal of Medical Information,2021,34(11):123.[doi:10.3969/j.issn.1006-1959.2021.04.032]

更新日期/Last Update: 1900-01-01